Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma

IF 2.9 4区生物学 Q3 CELL BIOLOGY Journal of Molecular Histology Pub Date : 2024-08-29 DOI:10.1007/s10735-024-10251-z

Chunyan Xu, Zhimin Lu, Guoxin Hou, Moran Zhu

{"title":"Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma","authors":"Chunyan Xu, Zhimin Lu, Guoxin Hou, Moran Zhu","doi":"10.1007/s10735-024-10251-z","DOIUrl":null,"url":null,"abstract":"<div><p>Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and is characterized by its heterogeneity and poor prognosis. The role of ribosomal proteins RPLP0, RPLP1 and RPLP2 in multiple cancers has been implicated. However, their function in LUAD and their correlation with the poor prognosis of LUAD remains elusive. In this study, we performed a comprehensive bioinformatic analysis of the impact of these ribosomal proteins on LUAD. Our findings reveal that RPLP0, RPLP1 and RPLP2 are overexpressed in LUAD, which are likely attributed to abnormal copy number variations and decreased methylation levels of their promoters. LUAD patients with high expression of RPLP0, RPLP1 or RPLP2 have worse clinical outcomes in terms of overall survival (OS), first progression (FP) and post-progression survival (PPS), indicating poor prognosis. Moreover, the expression of RPLP0, RPLP1 and RPLP2 affects immune cell infiltration in LUAD tissues. Finally, we identified multiple existing drugs that may inhibit the expression of RPLP1 and RPLP2. Collectively, our data implicate the oncogenic role of RPLP0, RPLP1 and RPLP2 in LUAD and underscore their prognostic value in LUAD patients.</p></div>","PeriodicalId":650,"journal":{"name":"Journal of Molecular Histology","volume":"55 6","pages":"1079 - 1091"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10735-024-10251-z.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Histology","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1007/s10735-024-10251-z","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and is characterized by its heterogeneity and poor prognosis. The role of ribosomal proteins RPLP0, RPLP1 and RPLP2 in multiple cancers has been implicated. However, their function in LUAD and their correlation with the poor prognosis of LUAD remains elusive. In this study, we performed a comprehensive bioinformatic analysis of the impact of these ribosomal proteins on LUAD. Our findings reveal that RPLP0, RPLP1 and RPLP2 are overexpressed in LUAD, which are likely attributed to abnormal copy number variations and decreased methylation levels of their promoters. LUAD patients with high expression of RPLP0, RPLP1 or RPLP2 have worse clinical outcomes in terms of overall survival (OS), first progression (FP) and post-progression survival (PPS), indicating poor prognosis. Moreover, the expression of RPLP0, RPLP1 and RPLP2 affects immune cell infiltration in LUAD tissues. Finally, we identified multiple existing drugs that may inhibit the expression of RPLP1 and RPLP2. Collectively, our data implicate the oncogenic role of RPLP0, RPLP1 and RPLP2 in LUAD and underscore their prognostic value in LUAD patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探讨肺腺癌中 RPLP0、RPLP1 和 RPLP2 表达的功能和预后价值

肺腺癌（LUAD）是非小细胞肺癌（NSCLC）中最常见的亚型，其特点是异质性和预后不良。核糖体蛋白 RPLP0、RPLP1 和 RPLP2 在多种癌症中的作用已被证实。然而，它们在 LUAD 中的功能及其与 LUAD 不良预后的相关性仍不明确。在本研究中，我们对这些核糖体蛋白对 LUAD 的影响进行了全面的生物信息学分析。我们的研究结果表明，RPLP0、RPLP1 和 RPLP2 在 LUAD 中过表达，这可能是由于它们的启动子拷贝数异常变异和甲基化水平降低所致。RPLP0、RPLP1或RPLP2高表达的LUAD患者在总生存期（OS）、首次进展期（FP）和进展后生存期（PPS）方面的临床预后较差，表明预后不良。此外，RPLP0、RPLP1 和 RPLP2 的表达会影响免疫细胞在 LUAD 组织中的浸润。最后，我们发现了多种可抑制 RPLP1 和 RPLP2 表达的现有药物。总之，我们的数据表明 RPLP0、RPLP1 和 RPLP2 在 LUAD 中的致癌作用，并强调了它们在 LUAD 患者中的预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Molecular Histology 生物-细胞生物学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The Journal of Molecular Histology publishes results of original research on the localization and expression of molecules in animal cells, tissues and organs. Coverage includes studies describing novel cellular or ultrastructural distributions of molecules which provide insight into biochemical or physiological function, development, histologic structure and disease processes. Major research themes of particular interest include: - Cell-Cell and Cell-Matrix Interactions; - Connective Tissues; - Development and Disease; - Neuroscience. Please note that the Journal of Molecular Histology does not consider manuscripts dealing with the application of immunological or other probes on non-standard laboratory animal models unless the results are clearly of significant and general biological importance. The Journal of Molecular Histology publishes full-length original research papers, review articles, short communications and letters to the editors. All manuscripts are typically reviewed by two independent referees. The Journal of Molecular Histology is a continuation of The Histochemical Journal.